FDA trumpets 35 new drug approvals for 2012

The FDA gave its blessing to 35 new drugs during fiscal 2012, a number that matches last year's total--and that put the agency ahead of other regulators in approving new therapies first. But is the FDA's record a sign that biopharma has more winners on tap? Or simply that the agency has accelerated its own processes? Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.